tvax-008
Vaccineexperimental
Clinical trial activity
3 trials · 5 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
2
Phase 3
0
Phase 4
0
Earliest trial started Jun 1, 2023 (NCT07190742)
Timeline
Indications
Mechanism of action
- Hepatitis B virusImmunity, active
Hepatitis B virus immunity, active
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT07179653 | Phase 2 | Jan 22, 2025 | Fujian Medical University, Grand Theravac Life Sciences (Nanjing) Co., Ltd., Jiao Tong University, Sichuan University, Southern Medical University |
| NCT07204236 | Early Phase 1 (Phase 1) | Jan 18, 2024 | Grand Theravac Life Sciences (Nanjing) Co., Ltd. |
| NCT07190742 | Phase 2 | Jun 1, 2023 | Grand Theravac Life Sciences (Nanjing) Co., Ltd. |
Showing 3 of 3 trials
Page 1 / 1
Organizations
Research & Development (5)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Grand Theravac Life Sciences (Nanjing) Co., Ltd. | For profit | 3 | 3 | 2 | 2023 |
| Fujian Medical University | Academic/Hospital | 1 | 0 | 1 | 2025 |
| Jiao Tong University | Academic/Hospital | 1 | 0 | 1 | 2025 |
| Sichuan University | Academic/Hospital | 1 | 0 | 1 | 2025 |
| Southern Medical University | Academic/Hospital | 1 | 0 | 1 | 2025 |
5 organizations
Page 1 / 1